Eli Lilly’s (LLY) Profit Potential with Drugs Mounjaro and Zepbound is Exceptional
Eli Lilly (LLY) could be a leading stock for 2024 as its diabetes drug Mounjaro and its weight loss drug Zepbound are now available.
Eli Lilly (LLY) could be a leading stock for 2024 as its diabetes drug Mounjaro and its weight loss drug Zepbound are now available.
TJX (TJX) delivered solid profit growth last quarter which management says came from an increase in customer traffic across all brands.
S&P Global (SPGI) had accelerated revenue growth across all divisions last quarter. And analysts see better things in store in 2024.
DR Horton (DHI) stock has surged this month as investors anticipate lower interest rates in 2024, which should boost housing sales.
Merck (MRK) delivered good results last quarter. But this slow-growing company has a stock that’s been lackluster during 2023.
MasterCard (MA) delivered accelerating profit growth last quarter as its customers are paying up for its fraud prevention services.
Booking.com (BKNG) continues to delivers strong growth. But is the travel trend slowing down? Let’s take a closer look.
Fiserv (V) is a true value as profits are growing at a high-teens rate yet the stock has a P/E of just 15. I envision a solid move higher.
Ecolab (ECP) stock used to be a steady riser. But inflation and COVID knocked profits (and the stock) down. Now ECL looks good again.
There seems to be a Starbucks (SBUX) in every neighborhood. And management still sees profits growing 15% to 20% this year.
Apple (AAPL) might have a catalyst in its Apple Vision Pro. Good. It needs one with total revenue down 1% last quarter.
Old Dominion Freight Line (ODFL) is expected to have profit growth return to normal in 2024 Q1. But the news seems priced in.